BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34026291)

  • 1. A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models.
    Hsiao YW; Tao CL; Chuang EY; Lu TP
    J Adv Res; 2021 May; 30():113-122. PubMed ID: 34026291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway.
    Wei X; Jia Y; Lou H; Ma J; Huang Q; Meng Y; Sun C; Yang Z; Li X; Xu S; Yang X; Ji T; Gao Q
    Oncol Rep; 2019 Dec; 42(6):2768-2776. PubMed ID: 31638241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
    Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.
    Zheng YZ; Liang L
    Ann Diagn Pathol; 2018 Jun; 34():161-165. PubMed ID: 29661721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
    Dai C; Xie Y; Zhuang X; Yuan Z
    Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and verification of a ten-gene signature predicting overall survival for ovarian cancer.
    Liu J; Xu F; Cheng W; Gao L
    Exp Cell Res; 2020 Oct; 395(2):112235. PubMed ID: 32805252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
    Han X; Yang L; Tian H; Ji Y
    Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using machine learning to predict ovarian cancer.
    Lu M; Fan Z; Xu B; Chen L; Zheng X; Li J; Znati T; Mi Q; Jiang J
    Int J Med Inform; 2020 Sep; 141():104195. PubMed ID: 32485554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
    Zeng S; Liu S; Feng J; Gao J; Xue F
    Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.
    Hossain MA; Saiful Islam SM; Quinn JMW; Huq F; Moni MA
    J Biomed Inform; 2019 Dec; 100():103313. PubMed ID: 31655274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
    Zuo L; Li X; Tan Y; Zhu H; Xiao M
    J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
    Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
    Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
    Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway.
    Si X; Xu F; Xu F; Wei M; Ge Y; Chenge S
    Biomed Pharmacother; 2020 Mar; 123():109717. PubMed ID: 31865146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.